Biogen Inc. (NASDAQ:BIIB) on Friday reported better-than-expected fourth-quarter earnings.The company posted quarterly adjusted EPS of $1.99, beating the consensus of $1.59. The Alzheimer’s drug maker reported revenues of $2.28 billion, beating the consensus of $2.20 billion, down 7% on a reported and constant currency basis.“Our 2025 performance reflected continued focus on strong execution and financial discipline, driven by our revenue of nearly $1 billion from LEQEMBI, SKYCLARYS, ZURZUVAE, and QALSODY, ...

Biogen Inc. (NASDAQ:BIIB) on Friday reported better-than-expected fourth-quarter earnings.The company posted quarterly adjusted EPS of $1.99, beating the consensus of $1.59. The Alzheimer’s drug maker reported revenues of $2.28 billion, beating the consensus of $2.20 billion, down 7% on a reported and constant currency basis.“Our 2025 performance reflected continued focus on strong execution and financial discipline, driven by our revenue of nearly $1 billion from LEQEMBI, SKYCLARYS, ZURZUVAE, and QALSODY, ...

Core Insights - Biogen Inc. reported better-than-expected fourth-quarter earnings with adjusted EPS of $1.99, surpassing the consensus estimate of $1.59 [1] - The company generated revenues of $2.28 billion, exceeding the consensus of $2.20 billion, although this represents a 7% decline on both a reported and constant currency basis [1] Drug Performance - Fiscal 2025 revenue from growth products increased by 19% year-over-year, which helped offset the decline in revenue from multiple sclerosis products, excluding Vumerity [2] - Leqembi, an Alzheimer's drug, generated collaboration revenue of $47 million, with in-market sales reaching approximately $134 million, reflecting a 54% increase [3] - Multiple sclerosis revenue totaled $917 million, down 14% year-over-year (15% decline on a constant currency basis), with Tysabri sales decreasing from $415.4 million to $397.5 million [3] Rare Disease Revenue - Revenue from rare diseases decreased by 4% year-over-year to $514.6 million, with Spinraza's revenue declining from $421.4 million to $356.2 million [4] - Spinraza's fourth-quarter revenue fell by 15% year-over-year, influenced by shipment timing outside the U.S., while full-year revenue was down 2% [4] New Product Contributions - Skyclarys, a drug for Friedreich's ataxia, reported revenues of $133.4 million during the quarter, up from $102.2 million a year ago [5] - Skyclarys saw a 30% increase in global patients on therapy in 2025, with U.S. revenue of approximately $89 million driven by demand growth [6] - Zurzuvae, a postpartum depression drug, achieved fourth-quarter revenue of approximately $66 million, indicating strong demand growth [6] - Vumerity's revenue grew by 3% year-over-year in the fourth quarter to $181.1 million [6] Management Commentary - The President and CEO of Biogen highlighted that the 2025 performance was driven by nearly $1 billion in revenue from LEQEMBI, SKYCLARYS, ZURZUVAE, and QALSODY, along with pipeline progression and the resilience of the MS franchise [7]

Key Takeaways BIIB posted Q4 EPS of $1.99 and revenue of $2.28B, both beating estimates despite year-over-year declines.BIIB saw weakness in MS drugs and Spinraza, partly offset by growth from Leqembi, Skyclarys and Zurzuvae.BIIB guided 2026 adjusted EPS of $15.25-$16.25, above consensus, driving gains after the earnings release.Biogen (BIIB) reported fourth-quarter 2025 adjusted earnings per share (EPS) of $1.99, which beat the Zacks Consensus Estimate of $1.61. Earnings declined 42% year over year.Total r ...

Biogen (NasdaqGS:BIIB) Q4 2025 Earnings call February 06, 2026 08:30 AM ET Company ParticipantsChristopher A. Viehbacher - President and CEOPriya Singhal - Head of DevelopmentRobin C. Kramer - EVP and CFOTim Power - Head of Investor RelationsUmer Raffat - Senior Managing DirectorOperatorGood morning, my name is Ruth and I will be your conference operator today. At this time, I would like to welcome everyone to the Biogen fourth quarter and full year 2025 earnings call and business update. All lines have bee ...

Biogen (NasdaqGS:BIIB) Q4 2025 Earnings call February 06, 2026 08:30 AM ET Company ParticipantsAlexandria Hammond - Director and Head of TherapeuticsBrian Abrahams - Managing Director and Co-Head of Biotechnology ResearchChris Schott - Managing DirectorChristopher A. Viehbacher - President and CEODanielle Brill - Managing DirectorEvan David Seigerman - Managing Director and Head of Healthcare ResearchMike Yee - Global Head of Biotechnology ResearchPriya Singhal - Head of DevelopmentRobin C. Kramer - EVP and ...

Biogen (NasdaqGS:BIIB) Q4 2025 Earnings call February 06, 2026 08:30 AM ET Speaker1Good morning, my name is Ruth and I will be your conference operator today. At this time, I would like to welcome everyone to the Biogen fourth quarter and full year 2025 earnings call and business update. All lines have been placed on mute to prevent any background noise. After the speaker's remarks, there will be a question-and-answer session. If you would like to ask a question during this time, simply press star 1 on your ...

Core Insights - Biogen Inc. is preparing for its quarterly earnings release on February 6, 2026, with analysts predicting an earnings per share (EPS) of $1.60 and revenue of approximately $2.2 billion [1][6] Group 1: Product Development and Research - The Phase 2/3 DEVOTE study results for nusinersen, published in Nature Medicine, highlight Biogen's commitment to spinal muscular atrophy (SMA) treatment, demonstrating safety and efficacy across a broad patient group [2] - This development is expected to enhance Biogen's product portfolio and mitigate declining sales in other segments [2] Group 2: Market Challenges and Opportunities - Biogen faces challenges in multiple sclerosis (MS) drug sales due to increasing competition from generics and biosimilars [3] - Despite these challenges, the company is optimistic about growth prospects with newer products such as Vumerity, Skyclarys, and Zurzuvae, along with positive traction for its Alzheimer's drug, Leqembi, in the U.S. market [3][6] Group 3: Financial Indicators - Biogen's financial indicators present a mixed outlook, with a price-to-earnings (P/E) ratio of 16.84 and a price-to-sales ratio of 2.72, reflecting market assessments of its earnings and revenue [4] - The enterprise value to sales ratio is 2.99, and the enterprise value to operating cash flow ratio is 12.16, indicating market valuation of its sales and cash flow [4] - The company maintains a debt-to-equity ratio of 0.36, suggesting a relatively low level of debt compared to equity, and a current ratio of 2.72, indicating strong capability to meet short-term liabilities [5]

Key Takeaways BIIB will report Q4 results on Feb. 6, with consensus estimate for sales at $2.21B & EPS at $1.60 per share.Biogen faces MS drug declines from generics, but Vumerity, Skyclarys and Zurzuvae can show growth.BIIB's Alzheimer's revenues may have risen as U.S. Leqembi sales improve.Biogen (BIIB) will report fourth-quarter and full-year 2025 results on Feb. 6, before market open. In the last reported quarter, the company's earnings beat expectations by 23.65%. The Zacks Consensus Estimate for fourt ...

Core Insights - Biogen is stabilizing its business amidst a decline in its multiple sclerosis (MS) portfolio while developing new growth drivers and restructuring its cost structure, with 2026 anticipated as the beginning of a "transformational era" due to multiple late-stage programs generating key data [2] Cost Reset and Portfolio Discipline - The company has implemented significant operational changes, achieving $1 billion in gross cost savings and $800 million in net savings, alongside a 15% reduction in headcount to enhance agility [3] - Biogen has tightened its R&D portfolio discipline, resulting in a 26% reduction in R&D spending compared to three years ago, while maintaining 10 Phase III programs and five potential new products [4] New Medicines Offsetting MS Decline - Biogen has launched four new medicines targeting Alzheimer's disease, Friedreich's ataxia, postpartum depression, and ALS, which are now offsetting the decline in MS revenue, contributing approximately $1.9 billion with a growth rate of 53% [5] - The company is focusing on expanding Leqembi through blood-based diagnostics and subcutaneous dosing, with several key readouts approaching in 2026 [5]